Part 2: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely

White Diamond Research's detailed analysis exposes critical flaws in Veru's sabizabulin COVID-19 treatment trial, revealing questionable data integrity, methodological issues, and conflicts of interest that signal probable FDA rejection.

Ticker: VERU (NASDAQ)
Research Firm: White Diamond Research
Report URL: https://whitediamondresearch.com/research/part-2-new-red-flags-emerge-from-verus-phase-3-covid-trial-suggesting-an-fda-rejection-is-likely/
Position Disclosure: White Diamond Research is short Veru Inc. (NASDAQ: VERU) and stands to benefit from price declines.

Why It Matters

Sabizabulin's mechanism of action, originally developed for cancer, lacks credible scientific evidence for COVID-19 efficacy, with Veru's Chief Science Officer admitting minimal research went into repurposing
Trial design shows alarming randomization deficiencies with inadequate protocol details compared to industry standards, suggesting potential data manipulation
Evidence indicates more severe COVID-19 cases were concentrated in the placebo group, artificially inflating efficacy results
Longstanding relationships between Veru and key trial centers (particularly Inspira Medical Center) create significant conflicts of interest, compromising trial objectivity
Unlike all successful COVID EUA recipients (companies with $60B+ market caps), Veru's $1.2B valuation and extended FDA review timeline signal regulatory concerns
Parallels with Beyond Spring's rejected cancer drug suggest similar fate for Veru, as both drugs are tubulin disruptors with cardiovascular risk profiles

Between The Lines

Veru's unusual decision to publish a peer-reviewed article during FDA review (not after) invites additional scrutiny and suggests anticipation of rejection
Principal investigator at key trial site runs a ketamine/IV vitamin clinic and has ties to previous controversial biotech promotions
With only 200 subjects enrolled, statistical anomalies and potential unblinding could significantly skew trial outcomes
Every COVID treatment with extended FDA review timelines like Veru's has faced significant regulatory challenges or outright rejection
Sabizabulin relies on a "colchicine-like" mechanism despite colchicine failing in a much larger (1,200 patient) COVID trial

FAQs

Why is Veru's COVID-19 drug likely to be rejected by the FDA?

White Diamond Research identifies multiple red flags including questionable trial randomization, small sample size (200 patients), potential conflicts of interest with trial centers, and a drug mechanism lacking scientific rationale for COVID-19 treatment.

What is sabizabulin and how was it developed?

Sabizabulin is a tubulin disruptor originally developed as a cancer treatment. Veru hastily repurposed it for COVID-19 without substantial preclinical evidence, with the company's Chief Science Officer admitting the adaptation process took only a weekend.

How does Veru's trial compare to other successful COVID-19 treatments?

Unlike successful COVID-19 treatments that secured FDA approval, Veru's trial was significantly smaller (200 patients vs. thousands), lacked transparent randomization protocols, and came from a company with a much smaller market capitalization ($1.2B vs. $60B+).

What similarities exist between Veru's situation and Beyond Spring's rejected drug?

Both companies developed tubulin disruptors with similar cardiovascular risk profiles, both showed promising Phase 3 results initially, and both faced extended FDA reviews. Beyond Spring ultimately received an FDA rejection, causing its market value to collapse.

Why is publishing a peer-reviewed article during FDA review concerning?

Most pharmaceutical companies wait until after FDA decisions to publish peer-reviewed articles to avoid complicating the regulatory process. Veru's decision to publish during review is unusual and may indicate an attempt to build market support ahead of a negative FDA decision.

What specific trial design flaws does the report identify?

The report highlights inadequate randomization details, potential unblinding of patients, imbalances in COVID-19 severity between treatment and placebo groups, and lack of comprehensive sub-population analyses that would be standard in rigorous clinical trials.

Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://whitediamondresearch.com/research/part-2-new-red-flags-emerge-from-verus-phase-3-covid-trial-suggesting-an-fda-rejection-is-likely/, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.